image
Amedisys, Inc. AMED
Healthcare - Medical - Care Facilities - NASDAQ - US
Watchlist
$ 91.7
-0.207 %
$ 3.01 B
Market Cap
70.0
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one AMED stock under the worst case scenario is HIDDEN Compared to the current market price of 91.7 USD, Amedisys, Inc. is HIDDEN

AMED Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one AMED stock under the base case scenario is HIDDEN Compared to the current market price of 91.7 USD, Amedisys, Inc. is HIDDEN

AMED Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one AMED stock under the best case scenario is HIDDEN Compared to the current market price of 91.7 USD, Amedisys, Inc. is HIDDEN

AMED Intrinsic Value
HIDDEN
SHOW
2. FUNDAMENTAL ANALYSIS

Price Chart AMED

image
1M --%
6M -5%
1Y 1%
3Y -48%
5Y -110.0%
All
$98.0$98.0$96.0$96.0$94.0$94.0$92.0$92.0$90.0$90.0$88.0$88.0$86.0$86.0$84.0$84.0$82.0$82.015 Oct15 OctNov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '25
FINANCIALS
2.35 B REVENUE
5.01%
Growth Rates
1Year 5.01%
3Years 1.98%
5Years 3.73%
7Years 6.28%
10Years 6.90%
94.5 M OPERATING INCOME
-39.55%
Growth Rates
1Year -39.55%
3Years -27.87%
5Years -11.84%
7Years 2.69%
10Years 14.67%
38.2 M NET INCOME
491.53%
Growth Rates
1Year 491.53%
3Years -43.37%
5Years -21.49%
7Years 3.17%
10Years 11.29%
222 M OPERATING CASH FLOW
61.58%
Growth Rates
1Year 61.58%
3Years 5.48%
5Years 1.88%
7Years 11.15%
10Years 18.33%
-8.36 M INVESTING CASH FLOW
-23.85%
Growth Rates
1Year -23.85%
3Years 69.03%
5Years 52.69%
7Years 21.12%
10Years 5.22%
-48.9 M FINANCING CASH FLOW
44.10%
Growth Rates
1Year 44.10%
3Years -23.58%
5Years -3.98%
7Years -36.51%
10Years -5.41%
598 M REVENUE
1.77%
Growth Rates
1Year 5.01%
3Years 1.98%
5Years 3.73%
7Years 6.28%
10Years 6.90%
-19.6 M OPERATING INCOME
-64.70%
Growth Rates
1Year -39.55%
3Years -27.87%
5Years -11.84%
7Years 2.69%
10Years 14.67%
-25.1 M NET INCOME
-151.71%
Growth Rates
1Year 491.53%
3Years -43.37%
5Years -21.49%
7Years 3.17%
10Years 11.29%
70.3 M OPERATING CASH FLOW
-33.46%
Growth Rates
1Year 61.58%
3Years 5.48%
5Years 1.88%
7Years 11.15%
10Years 18.33%
-1.28 M INVESTING CASH FLOW
47.65%
Growth Rates
1Year -23.85%
3Years 69.03%
5Years 52.69%
7Years 21.12%
10Years 5.22%
-11.2 M FINANCING CASH FLOW
25.73%
Growth Rates
1Year 44.10%
3Years -23.58%
5Years -3.98%
7Years -36.51%
10Years -5.41%
Balance Sheet Amedisys, Inc.
image
Current Assets 632 M
Cash & Short-Term Investments 303 M
Receivables 296 M
Other Current Assets 32.8 M
Non-Current Assets 1.51 B
Long-Term Investments 0
PP&E 124 M
Other Non-Current Assets 1.38 B
14.18 %13.84 %5.78 %64.67 %Total Assets$2.1b
Current Liabilities 514 M
Accounts Payable 40 M
Short-Term Debt 63.9 M
Other Current Liabilities 411 M
Non-Current Liabilities 444 M
Long-Term Debt 396 M
Other Non-Current Liabilities 48.1 M
4.17 %6.66 %42.82 %41.34 %5.01 %Total Liabilities$958.7m
EFFICIENCY
Earnings Waterfall Amedisys, Inc.
image
Revenue 2.35 B
Cost Of Revenue 1.33 B
Gross Profit 1.02 B
Operating Expenses 923 M
Operating Income 94.5 M
Other Expenses 56.4 M
Net Income 38.2 M
3b3b2b2b2b2b1b1b500m500m002b(1b)1b(923m)95m(56m)38mRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
43.34% GROSS MARGIN
43.34%
Averages
1Year 43.34%
3Years 43.65%
5Years 43.60%
7Years 42.78%
10Years 42.61%
4.03% OPERATING MARGIN
4.03%
Averages
1Year 4.03%
3Years 6.38%
5Years 8.22%
7Years 8.50%
10Years 6.79%
1.84% NET MARGIN
1.84%
Averages
1Year 1.84%
3Years 2.25%
5Years 5.01%
7Years 5.53%
10Years 4.30%
3.81% ROE
3.81%
Averages
1Year 3.81%
3Years 4.73%
5Years 11.86%
7Years 14.84%
10Years 11.71%
2.02% ROA
2.02%
Averages
1Year 2.02%
3Years 2.52%
5Years 6.10%
7Years 8.17%
10Years 6.56%
2.48% ROIC
2.48%
Averages
1Year 2.48%
3Years 2.55%
5Years 7.35%
7Years 10.39%
10Years 7.09%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Amedisys, Inc.
image
300m300m250m250m200m200m150m150m100m100m50m50m0020162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income 38.2 M
Depreciation & Amortization 60.5 M
Capital Expenditures -6.55 M
Stock-Based Compensation 30.6 M
Change in Working Capital 39.9 M
Others 56.3 M
Free Cash Flow 215 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Amedisys, Inc.
image
Wall Street analysts predict an average 1-year price target for AMED of $106 , with forecasts ranging from a low of $85 to a high of $150 .
AMED Lowest Price Target Wall Street Target
85 USD -7.31%
AMED Average Price Target Wall Street Target
106 USD 15.99%
AMED Highest Price Target Wall Street Target
150 USD 63.58%
Price
Max Price Target
Min Price Target
Average Price Target
15015014014013013012012011011010010090908080May '24May '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 11
6. Ownership
Insider Ownership Amedisys, Inc.
image
Sold
0-3 MONTHS
188 K USD 1
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Why Is Amedisys (AMED) Up 1.3% Since Last Earnings Report? Amedisys (AMED) reported earnings 30 days ago. What's next for the stock? zacks.com - 3 weeks ago
Here's Why You Should Retain AMED Stock in Your Portfolio Now Amedisys' high Quality of Patient Care and Patient Satisfaction star ratings bring optimism to investors. Yet, a dull macroeconomic condition adds to the worry. zacks.com - 1 month ago
AMED Q4 Earnings and Revenues Miss, Margins Dip, Stock Rises Amedisys, for the fourth quarter of 2024, delivers year-over-year top-line growth across three of its segments - Home Health, Hospice and High Acuity Care. zacks.com - 1 month ago
Amedisys (AMED) Reports Q4 Earnings: What Key Metrics Have to Say While the top- and bottom-line numbers for Amedisys (AMED) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. zacks.com - 1 month ago
Amedisys (AMED) Lags Q4 Earnings and Revenue Estimates Amedisys (AMED) came out with quarterly earnings of $0.96 per share, missing the Zacks Consensus Estimate of $1.05 per share. This compares to earnings of $0.94 per share a year ago. zacks.com - 1 month ago
Amedisys Reports Fourth Quarter and Year End 2024 Financial Results BATON ROUGE, La., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three-month period and year ended December 31, 2024. globenewswire.com - 1 month ago
Amedisys (AMED) Earnings Expected to Grow: Should You Buy? Amedisys (AMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com - 2 months ago
Amedisys Honors 47 Employees With Annual Spirit of Excellence Award BATON ROUGE, La., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), a leading provider of home health, hospice and high-acuity care services, has recognized 47 employees with the prestigious Spirit of Excellence Awards, one of the company's highest honors. globenewswire.com - 2 months ago
3 Stocks to Gain From Trump's Family Caregiver Tax Credits President Trump has endorsed the passage of a tax credit for family caregivers. The tax credit would be given to caregivers who take care of a parent, family member, or a loved one. marketbeat.com - 2 months ago
UnitedHealth's $3.3B Merger Stalls as VitalCaring Sale Falls Through UNH and AMED are now expected to identify new buyers for the divestment assets by March 2025. zacks.com - 3 months ago
Reasons to Retain AMED Stock in Your Portfolio Now Amedisys' expected merger with UnitedHealth Group's Optum brings optimism to investors. Yet, a dull macroeconomic condition adds to the worry. zacks.com - 3 months ago
Midnight Sun Mining secures Kazhiba target license renewal - ICYMI Midnight Sun Mining Corp (TSX-V:MMA, OTCQB:MDNGF) director of marketing and communications Adrian O'Brien talked with Proactive about securing approval from Zambia's Mines Ministry for the renewal of the Kazhiba target license. He emphasized that the license is a cornerstone of the cooperative exploration plan with First Quantum Minerals (TSX:FM). Proactive: Exciting news about the company’s license renewal for your Kazhiba target. This is really the end of a long journey. Can you bring everyone up to date on where things stand? Adrian O'Brien: Certainly. We've just received approval from the Mines Ministry of Zambia for the renewal of the license covering our Kazhiba target. This is a crucial part of our cooperative exploration plan with First Quantum Minerals. We've been waiting for this approval for some time due to a clerical error last summer, which showed the license as rejected. Thankfully, the Zambian ministry was great, and the situation has been resolved. This renewal sets us up perfectly for moving forward. Now that you have the license in hand, what are the next steps for the company over the next three to six months? This approval is pivotal for our cooperative exploration with First Quantum. We have two primary targets—Kazhiba to the northwest and Mitu to the southwest of our property. Both have significant oxide copper concentrations at surface, identified through drilling. The plan is to continue exploration work to prove up resources. We’ve already started, and this renewal allows us to push forward, complete programs, and deliver results. We expect to announce assay results soon, so exciting times are ahead. You also mentioned near-term production opportunities and potential cash flow. Could you elaborate? Certainly. Kansanshi, First Quantum's flagship mine, is located about six kilometers from our property. It's the largest copper mining complex in Africa and has been operational for 20 years. However, its oxide copper supply has been depleted. Our property is now the only source of high-concentration oxides in the area. We aim to address their supply issues and support their operations for the next 5 to 10 years. Finally, there’s news about your agreement with Kobold Mining. Can you update us on that? Yes. We’ve amended the earning agreement to remove the long stop date. This gives us more flexibility to obtain the required environmental permits without repeatedly extending deadlines. We’re looking to start drilling aggressively after the rainy season, around March or April. Quotes have been lightly edited for clarity and style UnitedHealth Group Inc (NYSE:UNH, ETR:UNH) and Amedisys (NASDAQ:AMED) have agreed to extend the deadline for their $3.3 billion merger, facing ongoing scrutiny from the US Department of Justice (DOJ). The companies announced in a regulatory filing that the merger deadline will now be extended to 10 days after a final court decision is issued or December 31, 2025, whichever comes first. This development follows a lawsuit filed over a month ago by the DOJ and attorneys general from Maryland, New Jersey, and New York to block the merger. Regulators argue that the deal would reduce competition in the home health services market, potentially harming patients, insurers, and nurses. The original deadline for the merger was set for today. Under a new waiver agreement, the companies have adjusted financial terms, including a regulatory break fee of $275 million, which could rise to $325 million if specific asset divestitures are not completed by May 1. Other modifications to the agreement include changes to operational restrictions and conditions tied to government approvals. UnitedHealth first announced plans to acquire Amedisys in June 2023, seeking to integrate the home health and hospice care provider into its operations. Despite the regulatory challenges, the companies remain committed to completing the deal, which they believe will deliver significant synergies and growth opportunities. Shares of Amedisys added 4.7% at $90 on the update, while UnitedHealth stock was down 0.5% at about $508. https://www.proactiveinvestors.com - 3 months ago
8. Profile Summary

Amedisys, Inc. AMED

image
COUNTRY US
INDUSTRY Medical - Care Facilities
MARKET CAP $ 3.01 B
Dividend Yield 0.00%
Description Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, Personal Care, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients. The Hospice segment offers services that is designed to provide comfort and support for those who are dealing with a terminal illness, including cancer, heart disease, pulmonary disease, or Alzheimer's. The Personal Care segment provides assistance for patients with the activities of daily living. The High Acuity Care offers essential elements of inpatient hospital, skilled nursing facility care and palliative care to patients in their homes. As of December 31, 2021, the company owned and operated 331 home health care centers, 175 hospice care centers, and 14 personal-care, and 8 high acuity care centers in 38 states within the United States and the District of Columbia. Amedisys, Inc. was incorporated in 1982 and is headquartered in Baton Rouge, Louisiana.
Contact 3854 American Way, Baton Rouge, LA, 70816 https://www.amedisys.com
IPO Date Aug. 17, 1994
Employees 19000
Officers Mr. Scott G. Ginn CPA Executive Vice President, Chief Operating Officer & Chief Financial Officer Kendra Kimmons Vice President of Marketing & Communications & Media Relations Mr. Keith Blanchard Acting Chief Information Officer Mr. Pete Hartley Chief Technology Officer & Senior Vice President of Business Operations Systems Ms. Allyson Guidroz Chief Accounting Officer & Principal Accounting Officer Ms. Denise Bohnert Chief Compliance Officer Mr. Richard M. Ashworth President, Chief Executive Officer & Director Mr. Nick Muscato Chief Strategy Officer Ms. Jennifer Guckert Griffin Chief Legal Officer & Corporate Secretary Ms. Caitlin Franklin Acting Chief People Officer